admin – eisai china lnc.-nba直播小9直播

 admin – eisai china lnc.-nba直播小9直播

entries by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and msd k.k. (headquarters: tokyo, president: kyle tattle, “msd”), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) announced today that eisai has submitted an application in japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, lenvima® (generic name: lenvatinib mesylate), in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s keytruda® (generic name: pembrolizumab) as a treatment for patients with advanced renal cell carcinoma (rcc). this is the first application to be submitted in japan for this combination therapy.

kyorin pharmaceutical co., ltd. (headquarters: chiyoda-ku, tokyo, president and ceo: shigeru ogihara, “kyorin”), a subsidiary of kyorin holdings, inc. (headquarters: chiyoda-ku, tokyo, president and ceo: yutaka ogihara), and eisai co., ltd. (headquarters: bunkyo-ku, tokyo, ceo: haruo naito, “eisai”) have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four asean (association of southeast asian nations) member states; thailand, the philippines, malaysia and brunei. based on this agreement, eisai will acquire exclusive development and marketing rights from kyorin for the agent in the said four countries, and will be responsible for submitting a new drug application for the agent.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the european medicines agency (ema) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: lenvima® / kisplyx®, “lenvatinib”), in combination with anti-pd-1 therapy pembrolizumab (brand name: keytruda®), developed by merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) as a treatment f or patients with advanced renal cell carcinoma (rcc) and advanced endometrial carcinoma (ec), respectively.

eisai china policy on submission of ideas: 1. eisai china holdings ltd., its affiliates and subsidiaries (collectively, ” eisai china”) are committed to protecting the privacy of the information collected from external individuals and organizations through eisai china online opportunity submission process. information here refers to personal identifiable information and other personal data, as well […]

eisai china holdings ltd. / eisai china inc.   shanghai branch address: 39-40th floor, park place, no.1601 nanjing xi road, shanghai, p.r.c tel: 021–24192888    fax: 021–24192891    zip code: 200040 suzhou factory address: 168# xingpu road,suzhou industrial park,jiangsu province p.r.c tel: 86-512-69566776     fax: 86-512-62576776     zip code: 215126 beijing branch address: 2303-2306 room, 23th floor, sk building, no.a 6 jianguomenwai […]

accessibility features of the site

        eisai china is committed to making this website accessible to the broadest possible audience, regardless of technology or physical capability. to this end, we are working constantly to improve the overall usability of the site, using many of the existing international standards for accessibility on the internet as guidelines. images: • […]

legal notice

legal notice of eisai china inc. website please read the following legal notice carefully prior to using the corporate website (“the website”) of eisai china inc. (“eisai”), which includes nba直播小9直播 copyrights, trademarks and domain name, privacy, disclaimers, links, applicable laws and versions. by accessing the website, you agree and accept all terms of this legal notice, […]

privacy policy

eci personal information protection policy 1、eisai abides by all chinese laws and regulations on the provision and protection of personal information. 2、eisai obtains, processes and applies personal information lawfully. 3、eisai collects personal information using appropriate methods for specified purposes of use and does not use it in a way that is contrary with those purposes. […]


eisai china inc. is a pharmaceutical company wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company headquartered in tokyo, with strong r&d capabilities. eisai has been smoothly developing its business in china since the early 1990s, eisai china, inc. currently promotes more than 10 pharmaceutical brands in china, specializing in the central nervous […]